Pharma company challenges cancer treatment award
A Taiwanese pharmaceuticals company has challenged an award issued in a €2 billion ICC dispute over a blood cancer drug, arguing it was not allowed to defend itself against a claim raised later in the proceedings.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10